Literature DB >> 9740242

Predominant expression of CD44 splice variant v10 in malignant and reactive human skin lymphocytes.

S N Wagner1, C Wagner, U Reinhold, R Funk, M Zöller, M Goos.   

Abstract

The remarkable functional diversity of the cell surface receptor CD44 may be due to expression of multiple variant isoforms generated by alternative splicing of variant exons. Functional and correlative data implicate a role of CD44 variant isoforms in adhesion dependent processes such as lymphocyte recirculation and tumor progression and metastasis. We have analyzed 25 primary cutaneous lymphomas and 35 reactive lymphoid cell skin infiltrates or T cell-mediated skin diseases for the expression of CD44 variant isoforms. Irrespective of histologic typing, staging, and grading, cutaneous lymphomas as well as nonmalignant skin-infiltrating CD3+ CD4+ and CD8+ T and CD19+ B lymphocytes exhibited a strong expression of CD44v10 and a moderate expression of CD44v3 as determined by immunohistochemistry, immunofluorescence microscopy, and mRNA analysis. Expression of v5, v6, v7, and v9-containing CD44 variant isoforms was not detected. Furthermore, flow cytometry revealed expression of CD44v10 on a significant proportion of peripheral blood lymphocytes from Sézary's syndrome patients and a remarkable co-expression with cutaneous lymphocyte antigen. These results indicate a distinct CD44 variant isoform expression pattern associated with skin-homing lymphocytes different to lymphatic cells at noncutaneous sites. This differential expression pattern of CD44 variant isoforms may contribute to the development of lymphocyte skin infiltrates and/or the unique biologic behavior of cutaneous lymphomas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9740242     DOI: 10.1046/j.1523-1747.1998.00302.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  3 in total

1.  The C3H/HeJ mouse and DEBR rat models for alopecia areata: review of preclinical drug screening approaches and results.

Authors:  Jing Sun; Kathleen A Silva; Kevin J McElwee; Lloyd E King; John P Sundberg
Journal:  Exp Dermatol       Date:  2008-10       Impact factor: 3.960

2.  Chronic delayed-type hypersensitivity reaction as a means to treat alopecia areata.

Authors:  M Zöller; P Freyschmidt-Paul; M Vitacolonna; K J McElwee; S Hummel; R Hoffmann
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

3.  Development of a peptide inhibitor of hyaluronan-mediated leukocyte trafficking.

Authors:  M E Mummert; M Mohamadzadeh; D I Mummert; N Mizumoto; A Takashima
Journal:  J Exp Med       Date:  2000-09-18       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.